Elizabeth Collier Sizemore, MD
Psychiatry · Parkersburg, WVNPI 1871955666
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 34.3% of the total. Reporting peaked in 2021 at $1,481 and has fallen 97.9% since, to $32 in 2025.
Across 160 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$863
- Sunovion Pharmaceuticals Inc.$402
- Otsuka America Pharmaceutical, Inc.$309
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$220
- Teva Pharmaceuticals USA, Inc.$191
- Takeda Pharmaceuticals U.S.A., Inc.$159
- plus $374 from 7 others
What the payments were for
- Food & beverage$2,47198%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $863 |
| Sunovion Pharmaceuticals Inc. | 25 | $402 |
| Otsuka America Pharmaceutical, Inc. | 23 | $309 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $220 |
| Teva Pharmaceuticals USA, Inc. | 11 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $159 |
| Alkermes, Inc. | 6 | $103 |
| Johnson & Johnson | 5 | $87 |
| Neos Therapeutics, LP | 5 | $74 |
| Lundbeck LLC | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
How this compares
$2,518 in reported general payments places this provider in the 75th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 41 | $850 |
| Buspirone Hcl | 41 | $815 |
| Trazodone Hcl | 62 | $729 |
| Hydroxyzine Hcl | 34 | $724 |
| Gabapentin | 36 | $486 |
| Duloxetine Hcl | 26 | $418 |
| Mirtazapine | 18 | $394 |
| Clonazepam | 40 | $382 |
| Lorazepam | 43 | $265 |
| Risperidone | 16 | $260 |
| Aripiprazole | 18 | $229 |
| Bupropion XlBupropion Hcl | 20 | $228 |
| Paroxetine Hcl | 16 | $227 |
| Escitalopram Oxalate | 31 | $183 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $177 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Parkersburg
- Cindy DuganParkersburg$3K
- Cynthia PratherParkersburg$3K
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$173K
- Shahnoor KhanMartinsburg$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.